Mode
Text Size
Log in / Sign up
Phase 3 N=2,831 Randomized Double-blind Prevention

Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial

Pregnancy · Respiratory Distress Syndrome · Pregnancy Outcomes · Preterm Birth

Enrolled (actual)
2,831
Serious AEs
0.9%
Results posted
Jan 2019
Primary outcome: Primary: Neonatal Composite Outcome — 165; 202; 145; 184 Participants — p=0.02

Study Design & Population

Study type
Interventional
Phase
Phase 3
Interventions
Betamethasone (Drug); Placebo (Drug)
Age
Pediatric, Adult, Older Adult
Sex
Female
Sponsor
The George Washington University Biostatistics Center
Primary completion
Mar 2015

Outcome Measures

OutcomeResultp-value
PRIMARY
Neonatal Composite Outcome
165; 202; 145; 184; 48; 61 0.02 sig
SECONDARY
Number of Neonates With Severe Respiratory Complication,
114; 169; 93; 147; 20; 34 <0.001 sig
SECONDARY
Neonates Needing Immediate Resuscitation After Birth
206; 260 0.003 sig
SECONDARY
Number of Neonates With Respiratory Distress Syndrome
79; 89 0.36
SECONDARY
Number of Neonates With Transient Tachypnea of the Newborn
95; 138 0.002 sig
SECONDARY
Number of Infants With Neonatal Apnea
33; 37 0.57
SECONDARY
Number of Infants withChronic Lung Disease / Bronchopulmonary Dysplasia (BPD) Requiring Supplemental Oxygen
2; 9 0.04 sig
SECONDARY
Neonates With Pneumonia
6; 13 0.10
SECONDARY
Number of Neonates Needing Surfactant Administration
26; 43 0.03 sig
SECONDARY
Neonatal Outcome Composite
198; 249 0.004 sig
SECONDARY
Number of Neonates With Pulmonary Air Leak
5; 6 0.74
SECONDARY
Neonatal Death After 72 Hours of Delivery
2; 0 0.50
SECONDARY
Birth Weight
2637; 2654 0.32
SECONDARY
Birth Weight Less Than 10th Percentile
255; 220 0.13
SECONDARY
Gestational Age at Delivery
193; 213; 394; 386; 609; 568 0.10
SECONDARY
Number of Neonates With Necrotizing Enterocolitic (NEC)
0; 1
SECONDARY
Number of Infants With Neonatal Sepsis
9; 11 0.62
SECONDARY
Number of Neonates With Intraventricular Hemorrhage
2; 0
SECONDARY
Neonatal Morbidity Composite
81; 90 0.40
SECONDARY
Number of Neonates With Hypoglycemia
343; 210 <0.001 sig
SECONDARY
Time Until First Neonatal Feeding
5.5; 9.9 0.004 sig
SECONDARY
Neonatal Feeding Difficulty
211; 223 0.40
SECONDARY
Neonatal Hyperbilirubinemia
167; 140 0.15
SECONDARY
Number of Neonates With Hypothermia
132; 112 0.24
SECONDARY
Length of NICU or Nursery Stay
596; 629; 470; 518 0.09
SECONDARY
Median Length of Hospital Stay
7; 8 0.20
SECONDARY
Maternal Outcomes (Participant-based)
20; 32; 16; 16; 454; 431 0.08
SECONDARY
Hours From Randomization to Delivery
33.0; 30.6 0.57
SECONDARY
Median Length of Maternal Hospital Stay
3; 3 0.11

Summary

This is a randomized placebo controlled trial to evaluate whether antenatal corticosteroids can decrease the rate of neonatal respiratory support, thus decreasing the rate of NICU admissions and improving short-term outcomes in the late preterm infant. The use of antenatal corticosteroids has been shown to be beneficial in women at risk for preterm delivery prior to 34 weeks but has not been evaluated in those likely to deliver in the late preterm period

Eligibility Criteria

Inclusion Criteria

Singleton Pregnancy. A twin pregnancy reduced to singleton (either spontaneously or therapeutically) before 14,0 weeks by project gestational age is acceptable

Gestational age at randomization between 34,0 weeks and 36,5 weeks confirmed by study criteria

High probability of delivery in the late preterm period (any one of the following):

  • Membrane rupture as defined by the occurrence of any two of the following: pooling of fluid in the vaginal vault, positive Nitrazine test, ferning of vaginal fluid, positive AmniSure test; or any one of the following: indigo carmine pooling in the vagina after amnioinfustion, visible leakage of amniotic fluid from the cervix

or

  • Preterm labor with intact membranes. Preterm labor is defined as at least 6 regular uterine contractions in an observation period of no more than 60 minutes and at least one of the following: cervix greater than or equal to 3cm dilated or at least 75% effaced

or

  • Planned delivery by induction of labor or cesarean section in no less than 24 hours and no more than 7 days, as deemed necessary by the provider. An induction must be scheduled to start by 36,5 weeks at the latest, whereas a cesarean delivery must be scheduled by 36,6 weeks at the latest. Therefore the latest gestational age for randomization is 36,4 weeks for a planned induction. The planned delivery may be for any indication, such as the following: prior myomectomy, prior classical cesarean, intrauterine growth restriction (IUGR), oligohydramnios, preeclampsia, nonreassuring fetal heart rate tracing warranting delivery, abruption, placenta previa

Exclusion Criteria

  • Any prior antenatal corticosteroid course during the pregnancy because of potential contamination of the placebo group
  • Candidate for stress dose corticosteroids because of chronic steroid therapy to prevent suppression of adrenal gland, because of potential contamination of the placebo group
  • Twin gestation reduced to a singleton gestation at or after 14 weeks 0 days by project gestational age either spontaneously or therapeutically
  • Fetal demise, or known major fetal anomaly, including cardiac anomaly and hydrops
  • Maternal contraindication to betamethasone: hypersensitivity reaction to any components of the medication, idiopathic thromboycytopenic purpura, systemal fungal infection in case of exacerbation by betamethasone, use of amphotericin B due to the possibility of heart failure with concomitant betamethasone
  • Pre-gestational diabetes - exclude if the patient was on medication (insulin, glyburide) prior to pregnancy
  • Delivery expected within 12 hours of randomization, because of insufficient time of corticosteroids to confer benefit, including any of the following:

A. Rupture of Membranes (ROM) does not satisfy protocol criteria - exclude if the patient being evaluated for Preterm Premature Rupture of Membranes (pPROM), does not have preterm labor or planned delivery and does not satisfy the spontaneous membrane rupture criteria (any 2 of: positive Nitrazine test, pooling of fluid in the vaginal vault test or ferning of vaginal fluid; or indigo carmine pooling in the vagina after amnioinfusion; or visible leakage of amniotic fluid from the cervix) B. Rupture of the membranes in the presence of more than 6 contractions per hour or cervical dilation of 3 cm or more, unless oxytocin was withheld for at least 12 hours (other induction agents allowed) C. Chorioamnionitis - exclude if patient is diagnosed with chorioamnionitis D. Cervical dilation ≥ 8 cm E. Evidence of non-reassuring fetal status requiring immediate delivery

  • Participation in another interventional study that influences neonatal morbidity and mortality
  • Participation in this trial in a previous pregnancy
  • Delivery at a non-network hospital
  • At 36, 0 weeks to 36, 5 weeks and quota for 36 weeks already met. To ensure there is an adequate proportion of women presenting at 34 to 35 weeks of gestation, enrollment will be rest
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT01222247). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search